Impact of Pancreatic Ductal Occlusion on Postoperative Outcomes in Pancreatic Head Cancer Patients Undergoing Neoadjuvant Therapy

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2024 Jun 20

PMID 38900299

Authors

Yoshifumi Hidaka

Shiroh Tanoue

Takuro Ayukawa

Koji Takumi

Hirotsugu Noguchi

Michiyo Higashi

Tetsuya Idichi

Yota Kawasaki

Hiroshi Kurahara

Yuko Mataki

Takao Ohtsuka

Chihaya Koriyama

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic ductal occlusion can accompany pancreatic head cancer, leading to pancreatic exocrine insufficiency (PEI) and adverse effects on nutritional status and postoperative outcomes. We investigated its impact on nutritional status, body composition, and postoperative outcomes in patients with pancreatic head cancer undergoing neoadjuvant therapy (NAT).

Methods: We analyzed 136 patients with pancreatic head cancer who underwent NAT prior to intended pancreaticoduodenectomy (PD) between 2015 and 2022. Nutritional and anthropometric indices (body mass index [BMI], albumin, prognostic nutritional index [PNI], Glasgow prognostic score, psoas muscle index, subcutaneous adipose tissue index [SATI], and visceral adipose tissue index) and postoperative outcomes were compared between the occlusion (n = 78) and non-occlusion (n = 58) groups, in which 61 and 44 patients, respectively, ultimately underwent PD.

Results: The occlusion group showed significantly lower post-NAT BMI, PNI, and SATI (p = 0.011, 0.005, and 0.015, respectively) in the PD cohort. The occlusion group showed significantly larger main pancreatic duct, smaller pancreatic parenchyma, and greater duct-parenchymal ratio (p < 0.001), and these morphological parameters significantly correlating with post-NAT nutritional and anthropometric indices. Postoperative 3-year survival and recurrence-free survival (RFS) rates were significantly poorer (p = 0.004 and 0.013) with pancreatic ductal occlusion, also identified as an independent postoperative risk factor for overall survival (hazard ratio [HR]: 2.31, 95% confidence interval [CI] 1.08-4.94, p = 0.030) and RFS (HR: 2.03, 95% CI 1.10-3.72, p = 0.023), in multivariate analysis.

Conclusions: Pancreatic ductal occlusion may be linked to poorer postoperative outcomes due to PEI-related malnutrition.

Citing Articles

Association between preoperative inflammatory status via CALLY index and postoperative pneumonia occurrence in resectable esophageal squamous cell carcinoma patients: a retrospective cohort study.

Fan M, Zhu Y, Qian L, Hu C, Ding H Front Oncol. 2025; 15:1486983.

PMID: 40034601 PMC: 11872739. DOI: 10.3389/fonc.2025.1486983.

Predictive role of the prognostic nutritional index for long-term prognosis among patients undergoing pancreatoduodenectomy: a meta-analysis.

Liu Y, Li K BMC Surg. 2025; 25(1):51.

PMID: 39881321 PMC: 11776240. DOI: 10.1186/s12893-024-02757-w.

References

Mourtzakis M, Prado C, Lieffers J, Reiman T, McCargar L, Baracos V . A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997-1006. DOI: 10.1139/H08-075. View

Wente M, Bassi C, Dervenis C, Fingerhut A, Gouma D, Izbicki J . Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007; 142(5):761-8. DOI: 10.1016/j.surg.2007.05.005. View

Okada K, Kawai M, Hirono S, Satoi S, Yanagimoto H, Ioka T . Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol. 2016; 78(4):719-26. DOI: 10.1007/s00280-016-3121-8. View

Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar J, Besselink M, Bonsing B . Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020; 38(16):1763-1773. PMC: 8265386. DOI: 10.1200/JCO.19.02274. View

Okada K, Hirono S, Kawai M, Miyazawa M, Shimizu A, Kitahata Y . Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer. Anticancer Res. 2017; 37(2):853-858. DOI: 10.21873/anticanres.11389. View

Okumura S, Kaido T, Hamaguchi Y, Fujimoto Y, Masui T, Mizumoto M . Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery. 2015; 157(6):1088-98. DOI: 10.1016/j.surg.2015.02.002. View

Sandini M, Patino M, Ferrone C, Alvarez-Perez C, Honselmann K, Paiella S . Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. JAMA Surg. 2018; 153(9):809-815. PMC: 6583880. DOI: 10.1001/jamasurg.2018.0979. View

Roeyen G, Berrevoet F, Borbath I, Geboes K, Peeters M, Topal B . Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. ESMO Open. 2022; 7(1):100386. PMC: 8819032. DOI: 10.1016/j.esmoop.2022.100386. View

Seza K, Yamaguchi T, Ishihara T, Tadenema H, Tawada K, Saisho H . A long-term controlled trial of endoscopic pancreatic stenting for treatment of main pancreatic duct stricture in chronic pancreatitis. Hepatogastroenterology. 2012; 58(112):2128-31. DOI: 10.5754/hge09346. View

10.

Bruno M, Haverkort E, Tijssen G, Tytgat G, van Leeuwen D . Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998; 42(1):92-6. PMC: 1726970. DOI: 10.1136/gut.42.1.92. View

11.

Seiler C, Izbicki J, Varga-Szabo L, Czako L, Fiok J, Sperti C . Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension. Aliment Pharmacol Ther. 2013; 37(7):691-702. PMC: 3601428. DOI: 10.1111/apt.12236. View

12.

Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M . Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter. Medicine (Baltimore). 2016; 95(18):e3582. PMC: 4863804. DOI: 10.1097/MD.0000000000003582. View

13.

Karasawa E, GOLDBERG H, Moss A, Federle M, London S . CT pancreatogram in carcinoma of the pancreas and chronic pancreatitis. Radiology. 1983; 148(2):489-93. DOI: 10.1148/radiology.148.2.6867347. View

14.

Groot V, Gemenetzis G, Blair A, Rivero-Soto R, Yu J, Javed A . Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019; 269(6):1154-1162. PMC: 6191366. DOI: 10.1097/SLA.0000000000002734. View

15.

Pecorelli N, Carrara G, De Cobelli F, Cristel G, Damascelli A, Balzano G . Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Br J Surg. 2016; 103(4):434-42. DOI: 10.1002/bjs.10063. View

16.

Evans D, Rich T, Byrd D, Cleary K, Connelly J, Levin B . Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127(11):1335-9. DOI: 10.1001/archsurg.1992.01420110083017. View

17.

Geer R, Brennan M . Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165(1):68-72; discussion 72-3. DOI: 10.1016/s0002-9610(05)80406-4. View

18.

Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M . The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017; 161(3):584-591. DOI: 10.1016/j.surg.2016.11.014. View

19.

Forsmark C, Tang G, Xu H, Tuft M, Hughes S, Yadav D . The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent. Aliment Pharmacol Ther. 2020; 51(10):958-967. PMC: 7299155. DOI: 10.1111/apt.15698. View

20.

Mokdad A, Minter R, Zhu H, Augustine M, Porembka M, Wang S . Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. J Clin Oncol. 2016; 35(5):515-522. DOI: 10.1200/JCO.2016.68.5081. View